Sean Madsen

Company: Bristol Myers Squibb

Job title: Principal Scientist

Seminars:

Panel: Debating Best Approaches to Assess Potency Beyond Interferon Gamma 12:15 pm

Why was IFN-gamma considered the gold standard potency method?  What other readouts should be evaluated besides killing and IFN-gamma?  How best should we transition from early to late-stage/commercial control strategies? What data or responses are desired to support the addition of other readouts to control strategies? Read more

day: Day 1 Track C AM